Protecting and enhancing IP value in technology licensing partnerships

In April 2017 two notable commercial announcements illustrated the potential challenges and financial strain surrounding the supplier-producer relationship and the underlying importance of the IP rights central to the partnership. The IP transaction announcements referenced below highlight the financial impacts of the value of intellectual property to technology companies and the suppliers of innovative technologies.

View the full article from IAM or download.

IP valuation for medical device innovations affected by US policy changes?

Innovative groups including companies of all sizes, universities and individuals seek to maximise the value of their intellectual property by investing in R&D activities and pursuing patent protection. Medical device companies are particularly focused on converting R&D efforts into patent-protected products. However, these companies and innovators face constant challenges resulting from numerous changes in regulations, pricing coverage, tax regimes and IP rights. As a result, corresponding IP values within the medical device industry appear to be declining based on a study of identified licensing transactions and royalty rates. To improve IP value, licensors must focus on demonstrating product and technology value to differentiate their licensing opportunity from others on the market and to command higher royalty rates, better deal terms and potential multiple licensing opportunities across different end markets and licensees.

View the full article from IAM or download here.